New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma
Natera announced the publication of a prospective study in Blood Neoplasia validating Signatera for molecular residual disease assessment in lymphoma, showing 100% positive predictive value at end-of-treatment compared to 62% for PET/CT scans. The study of 144 patients found Signatera was the strongest independent predictor of event-free survival (HR 80.83 vs 5.18 for imaging) and demonstrated 91% sensitivity and 92% specificity during surveillance.
Key figures
- Cohort size
- 144
- Ppv pet ct eot
- 62%
- Hr eot adjusted
- 45.33
- Hr surveillance
- 33.74
- Ppv signatera eot
- 100%
- Hr multivariate pet ct
- 5.18
- Plasma samples analyzed
- 1105
- Sensitivity surveillance
- 91%
- Specificity surveillance
- 92%
- Hr multivariate signatera
- 80.83
- Median durable treatment positive
- 1.97 months
- Median durable treatment clearance
- 16.1 months
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.